共 46 条
[1]
Cunningham D(2004)Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 337-345
[2]
Humblet Y(2007)Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer J Clin Oncol 25 1658-1664
[3]
Siena S(2005)Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti-EGFR treatment in colorectal cancer: a cohort study Lancet Oncol 6 279-286
[4]
Van Cutsem E(2005)Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab J Clin Oncol 25 3238-3245
[5]
Peeters M(2007)EGFR FISH assay predicts for response to cetuximab in chemotherapy refractorycolorectal cancer patients Ann Oncol 19 717-723
[6]
Siena S(2008)Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study Clin Cancer Res 14 5869-5876
[7]
Moroni M(2007)Cetuximab for the treatment of colorectal cancer N Engl J Med 357 2040-2048
[8]
Veronese S(2008)Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 1582-1584
[9]
Benvenuti S(2007)Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab J Clin Oncol 25 3230-3237
[10]
Sartore-Bianchi A(2006)KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer Cancer Res 66 3992-3995